Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib

Urologic Oncology: Seminars and Original Investigations

Volumn 32, Issue 5, 2014, Pages 584-588

  Miyake, Hideaki ^a   Nishikawa, Masatomo ^a   Tei, Hiromoto ^a   Furukawa, Junya ^a   Harada, Ken ichi ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Matrix metalloproteinase; Renal cell carcinoma; Resistance; Sunitinib; Tissue inhibitor of metalloproteinases

Indexed keywords

C REACTIVE PROTEIN; GELATINASE A; GELATINASE B; SUNITINIB; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; MMP9 PROTEIN, HUMAN; PYRROLE DERIVATIVE; TIMP2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; REPEATED DRUG DOSE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CARCINOMA, RENAL CELL; KIDNEY NEOPLASMS; METASTASIS; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; RETROSPECTIVE STUDIES; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84902553812     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.01.016     Document Type: Article

References (23)

1. Rini B.I., Rathmell W.K., Godley P. Renal cell carcinoma. Curr Opin Oncol 2008, 20:300-316.
2. Parton M., Gore M., Eisen T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J Clin Oncol 2006, 24:5584-5592.
3. Figlin R., Sternberg C., Wood C.G. Novel agents and approaches for advanced renal cell carcinoma. J Urol 2012, 188:707-715.
4. Gan H.K., Seruga B., Knox J.J. Sunitinib in solid tumors. Expert Opin Investig Drugs 2009, 18:821-834.
5. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003, 9:327-337.
6. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon-α in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
7. Hutson T.E., Figlin R.A., Kuhn J.G., et al. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
8. Fyfe G., Fisher R.I., Rosenberg S.A., Sznol M., Parkinson D.R., Louie A.C. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995, 13:688-696.
9. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
10. Keefe S.M., Nathanson K.L., Rathmell W.K. The molecular biology of renal cell carcinoma. Semin Oncol 2013, 40:421-428.
11. Yoon S.O., Park S.J., Yun C.H., Chung A.S. Roles of matrix metalloproteinases in tumor metastasis and angiogenesis. J Biochem Mol Biol 2003, 36:128-137.
12. Cruz-Munoz W., Khokha R. The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis. Crit Rev Clin Lab Sci 2008, 45:291-338.
13. Yuasa T., Takahashi S., Hatake K., Yonese J., Fukui I. Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. Cancer Sci 2011, 102:1949-1957.
14. Rini B.I., Cohen D.P., Lu D.R., et al. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2011, 103:763-773.
15. Perez-Gracia J.L., Prior C., Guillén-Grima F., et al. Identification of TNF-α and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 2009, 101:1876-1883.
16. Porta C., Paglino C., De Amici M., et al. Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib. Kidney Int 2010, 77:809-815.
17. Terakawa T., Miyake H., Kusuda Y., Fujisawa M. Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib. Urol Oncol 2013, 31:493-498.
18. Sakai I., Miyake H., Fujisawa M. Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation. BJU Int 2013, 112:E211-E220.
19. Kunigal S., Lakka S.S., Joseph P., Estes N., Rao J.S. Matrix metalloproteinase-9 inhibition down-regulates radiation-induced nuclear factor-κ B activity leading to apoptosis in breast tumors. Clin Cancer Res 2008, 14:3617-3626.
20. Asuthkar S., Velpula K.K., Chetty C., Gorantla B., Rao J.S. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget 2012, 3:1439-1454.
21. Tsagaraki I., Tsilibary E.C., Tzinia A.K. TIMP-1 interaction with αvβ3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF-α-induced apoptosis. Cell Tissue Res 2010, 342:87-96.
22. Toricelli M, Melo FH, Peres GB, Silva DC, Jasiulionis MG. Timp1 interacts with beta-1 integrin and CD63 along melanoma genesis and confers anoikis resistance by activating PI3-K signaling pathway independently of Akt phosphorylation. Mol Cancer 2013;12:22.
23. Porta C., Paglino C., Imarisio I., et al. Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 2013, 84:115-122.